Prevalence and genotype distribution of HPV combined with cervical pathological results in women from Sichuan, China: A cross‐sectional study based on post‐vaccination period 2019 to 2023

Abstract

BackgroundHuman papillomavirus (HPV) screening and vaccination exert efficacy in controlling the progression of cervical cancer. Thus, examinations into HPV prevalence, age‐stratified specificity, genotype distribution, and their correlation with pathological outcomes can furnish robust evidence for customizing high‐quality population screening and management.MethodsA cohort of 17,923 women attending clinics in the Jintang area, Sichuan, from January 2019 through August 2023 were enrolled in the study. Genotyping of HPV was conducted using real‐time polymerase chain reaction (RT‐PCR). The epidemiology and the relationship between HPV infection and histologic/cytologic abnormalities were subjected to analysis.ResultsHPV infection was identified in 4387 women. The outpatient group exhibited a significantly higher HPV infection rate compared to the healthy examination group (26.5% vs. 17.5%, p < 0.05). The distribution of infection rates across different age groups exhibited a U‐shaped pattern, with the highest infection rate in the group ≤20 years of age, succeeded by those >60 years of age. The 31–40 age group demonstrated the lowest prevalence of infection, but upon infection, its prevalence of the precancerous lesion CIN2‐3 reached a maximum of 29.0%, constituting a novel finding. The most prevalent genotype was HPV52, followed by HPV16, 58, 53, 68, and 18. In the cytologic and histologic abnormalities group, the most common types were HPV52, 16, and 58. HPV16 predominantly appeared in high‐grade intraepithelial neoplasia and carcinoma in situ, constituting over 60% of cases. While HPV type 52 was not individually detected in cervical cancer cases. And some other non‐vaccine‐covered HPV subtypes also showed high prevalence in Sichuan. The single infection rates of NH9‐HPV (high‐risk HPV subtypes covered by the non‐nine‐valent vaccine) in CIN2‐3 and cervical cancer patients were 6.5% and 2.6%, respectively. Among them, HPV51, HPV53, HPV59, and HPV35 exhibited a significant preponderance, which even higher than HPV45 and HPV31 covered by the nine‐valent vaccine types. And in NL9‐HPV (low‐risk HPV subtypes covered by the non‐nine‐valent vaccine), HPV42 accounted for the highest percentage in CIN2‐3. A similar decreasing trend was observed in annual infection rates in the healthy examination population and in the 31–40 and 51–60 age groups, while the ≤20 age group showed an increase. Regarding type‐specificity, HPV16 and HPV58 exhibited the most rapid declines.ConclusionThis study furnishes the latest insights into the characteristics of HPV infection rate, age distribution, and genotype prevalence in Sichuan.